GSK - GlaxoSmithKline plc
LSE
->
Healthcare
->
Drug Manufacturers—General
Brentford,
United Kingdom
Type: Equity
GSK price evolution
GSK
| (in millions $) | 31 Mar 2024 | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2790 | $2936 | $3177 | $3140 |
| Short term investments | $1305 | $2246 | $3506 | $114 |
| Net receivables | $7291 | $7758 | $8874 | $7095 |
| Inventory | $5702 | $5498 | $5480 | $5512 |
| Total current assets | $17205 | $18644 | $21240 | $19348 |
| Long term investments | $1277 | $1192 | $1142 | $1350 |
| Property, plant & equipment | $9867 | $9957 | $9454 | $9315 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $58511 | $59005 | $60862 | $59461 |
| Current liabilities | ||||
| Accounts payable | $13707 | $14996 | $14692 | $13101 |
| Deferred revenue | ||||
| Short long term debt | $2616 | $2813 | $4843 | $5921 |
| Total current liabilities | $19846 | $21068 | $22390 | $22108 |
| Long term debt | $15156 | $15205 | $15999 | $15553 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $45282 | $46210 | $48243 | $47302 |
| Shareholders' equity | ||||
| Retained earnings | $7935 | $7239 | $7017 | $6418 |
| Other shareholder equity | $475 | $757 | $804 | $943 |
| Total shareholder equity | $13229 | $12795 | $12619 | $12159 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $2936 | $879 | $1427 | $8054 |
| Short term investments | $2246 | $750 | $614 | $4608 |
| Net receivables | $7758 | $7458 | $8031 | $7264 |
| Inventory | $5498 | $5146 | $5783 | $5996 |
| Total current assets | $18644 | $20769 | $18674 | $20247 |
| Long term investments | $1192 | $1575 | $2276 | $3424 |
| Property, plant & equipment | $9957 | $9620 | $10672 | $11006 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $77276.25 | |||
| Total investments | ||||
| Total assets | $59005 | $60146 | $79103 | $80431 |
| Current liabilities | ||||
| Accounts payable | $14996 | $16263 | $4535 | $4357 |
| Deferred revenue | ||||
| Short long term debt | $2813 | $3952 | $3601 | $3725 |
| Total current liabilities | $21068 | $22810 | $23670 | $22148 |
| Long term debt | $15205 | $17035 | $20572 | $23425 |
| Total noncurrent liabilities | $48117.9 | |||
| Total debt | ||||
| Total liabilities | $46210 | $49548 | $64048 | $65844 |
| Shareholders' equity | ||||
| Retained earnings | $7239 | $5811 | $10073 | $8884 |
| Other shareholder equity | $757 | -$373 | -$21 | -$31 |
| Total shareholder equity | $12795 | $10096 | $21342 | $14587 |
| (in millions $) | 31 Mar 2024 | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $7363 | $8147 | $7178 | |
| Cost of revenue | $1918 | $2243 | $1899 | |
| Gross Profit | $5445 | $5904 | $5279 | |
| Operating activities | ||||
| Research & development | $1373 | $1448 | $1335 | |
| Selling, general & administrative | $2070 | $2212 | $2257 | |
| Total operating expenses | $4601 | $5591 | $5127 | |
| Operating income | $2762 | $2556 | $2051 | |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $274 | $257 | $242 | |
| Interest expense | -$164 | -$180 | -$185 | |
| Net income | ||||
| Net income | $1046 | $1464 | $1624 | |
| Income (for common shares) | $1046 | $1464 | $1624 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $30328 | $29324 | $34114 | $34099 |
| Cost of revenue | $8388 | $9407 | $11454 | $10890 |
| Gross Profit | $21940 | $19917 | $22660 | $23209 |
| Operating activities | ||||
| Research & development | $5823 | $5153 | $4877 | $4603 |
| Selling, general & administrative | $9156 | $8179 | $10190 | $10717 |
| Total operating expenses | $22414 | $22002 | $26148 | $26316 |
| Operating income | $7914 | $7322 | $7966 | $7783 |
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $756 | $707 | $346 | $580 |
| Interest expense | -$784 | -$819 | -$775 | $1220 |
| Net income | ||||
| Net income | $4928 | $14956 | $4385 | $5749 |
| Income (for common shares) | $4928 | $14956 | $4385 | $5749 |
| (in millions $) | 31 Mar 2024 | 31 Jan 2024 | 30 Sep 2023 | 30 Jun 2023 |
|---|---|---|---|---|
| Net income | $1046 | $1464 | $1624 | |
| Operating activities | ||||
| Depreciation | $353 | $397 | $268 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $958 | $2212 | $1307 | |
| Investing activities | ||||
| Capital expenditures | -$248 | -$299 | -$296 | |
| Investments | ||||
| Total cash flows from investing | -$149 | -$1595 | -$491 | -$964 |
| Financing activities | ||||
| Dividends paid | -$568 | -$2247 | -$567 | -$557 |
| Sale and purchase of stock | $18 | $3 | ||
| Net borrowings | -$380 | -$1098 | $989 | |
| Total cash flows from financing | -$1060 | -$5641 | -$1762 | $31 |
| Effect of exchange rate | -$99 | |||
| Change in cash and equivalents | -$270 | -$567 | -$18 | $317 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $4928 | $14956 | $4385 | $6388 |
| Operating activities | ||||
| Depreciation | $1732 | $2002 | $1195 | $1214 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $6768 | $7403 | $7952 | $8441 |
| Investing activities | ||||
| Capital expenditures | -$1314 | -$1143 | -$1172 | -$2239 |
| Investments | ||||
| Total cash flows from investing | -$1595 | -$8772 | -$1777 | $2161 |
| Financing activities | ||||
| Dividends paid | -$2247 | -$3467 | -$3999 | -$3977 |
| Sale and purchase of stock | $10 | $25 | $21 | $29 |
| Net borrowings | -$2567 | -$4824 | -$2210 | -$4234 |
| Total cash flows from financing | -$5641 | $823 | -$7589 | -$10132 |
| Effect of exchange rate | -$29 | -$39 | ||
| Change in cash and equivalents | -$567 | -$394 | -$1443 | $431 |
News
|
12 Best Biotech Penny Stocks to Invest In
Insider Monkey via Yahoo Finance
24 Mar 2024
|
|
The Zacks Analyst Blog Highlights Booz Allen Hamilton, Molson Coors Beverage, Tyson Foods,...
Zacks via Yahoo Finance
14 Mar 2024
|
|
Inflation Remains Sticky in February: 5 Safe Picks
Zacks via Yahoo Finance
13 Mar 2024
|
|
FTSE 100: GSK tops forecasts after strong sales of shingles vaccine
Yahoo Finance UK
1 Feb 2023
|
|
The Zacks Analyst Blog Highlights Caterpillar, Equinor, GSK, Sysco and AmerisourceBergen
Zacks via Yahoo Finance
10 Jan 2023
|
|
Billionaire Steve Cohen’s Top 10 Dividend Stocks
Insider Monkey via Yahoo Finance
19 Nov 2022
|
|
12 Best Ethical Stocks To Buy Now
Insider Monkey via Yahoo Finance
11 Oct 2022
|
|
2 Dividend Stocks to Double Up On Right Now
Motley Fool
28 Sep 2022
|
|
GlaxoSmithKline (GSK) Gains As Market Dips: What You Should Know
Zacks via Yahoo Finance
18 Sep 2022
|
|
GSK Completes Demerger of Consumer Healthcare Business
Zacks via Yahoo Finance
19 Jul 2022
|
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | 5.93% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 3.61 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.87 |
| Quick ratio | 0.58 |